Tools
Repaglinide
Indications
Repaglinide is a drug used in the treatment of diabetes mellitus type 2. It belongs to a class of antihyperglycemic agents known as meglitinides, along with nateglinide. Meglitinides work to reduce blood glucose levels by stimulating endogenous insulin production. The present recommended starting dose is dependent on hemoglobin A1c levels, with those below 8% (64 mmol/mol) urged to start with 0.5 mg pre-prandially and those above 8% to start with 1 to 2 mg.
Repaglinide may be used as monotherapy (supplemental to exercise and diet control) or in combination with other antihyperglycemic agents (metformin or others, if metformin is not tolerated/contraindicated). The exception is using sulfonylureas (e.g., gliclazide, glipizide), which is a contraindication for dual therapy with meglitinides. Research has suggested that repaglinide is a favorable treatment choice in patients with chronic kidney disease and end-stage renal disease.
Repaglinide is FDA class C during pregnancy, meaning its use requires caution. There has been no evidence to support its safe use during breastfeeding, and thus an alternative is recommended.
The safety of repaglinide in children under the age of 18 has not been established and, as such, is not recommended.
Repaglinide should be taken shortly before meals and should be omitted when skipping meals.[1][2][3][4][5][6]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Repaglinide is an insulin secretagogue, meaning it binds to receptors on pancreatic beta cells and stimulates insulin release. Repaglinide binds to an ATP-dependent potassium channel on beta cells, known as SUR1, bringing about its closure. This mechanism of action is similar to that of the sulfonylureas, and as a result, the concurrent use of these therapies is contraindicated.
Repaglinide demonstrates a concentration-response relationship in the presence of glucose, with a maximal secretory response of approximately 10 nmol/L. Studies suggest repaglinide reduces postprandial glucose in the order of around 5.8 mmol/L and fasting glucose around 3.1 to 3.4 mmol/L.
Repaglinide is rapidly absorbed, with a half-life of fewer than 60 minutes. The fast onset and short duration of action of repaglinide have made it one of the most appropriate therapies for managing postprandial glucose spikes, and as such, it is recommended approximately 30 minutes before an intended meal.
In the body, repaglinide binds to albumin at around 98% concentration and is associated with a more significant reduction in glycated albumin than sulfonylureas.
Repaglinide is inactivated and excreted via the liver, and as such, concomitant use of other therapies associated with liver metabolism should be considered.[7][8][9][10][11][12]
Administration
Oral administration of repaglinide, between 0.5 to 4 mg twice to three times daily, to a maximum of 16 mg, produces glycemic control in a similar order to other antihyperglycemic agents. Repaglinide should be administered approximately 30 minutes before an intended meal, and the dose skipped if a scheduled mealtime is skipped. Dose adjustments should be reviewed a minimum of one week later.[2][5][13]
Adverse Effects
The most commonly reported side effect associated with repaglinide monotherapy is hypoglycemia (7% in a study of 76 patients), followed by weight gain (1.8 kg / 16 weeks). Whipple triad for hypoglycemia is defined as the presence of symptoms of hypoglycemia, presence of factual hypoglycemia (<50 mg/dl), and correction of the symptoms after administration of glucose.
Repaglinide has reports showing it to be of greater risk of cardiovascular events than metformin but lesser than sulfonylureas.
Other adverse reactions of note included upper respiratory tract infection and sinusitis when trialed versus placebo. There are reports of weight gain, diarrhea, and joint pain.
Reports of hypoglycemia are more frequent when repaglinide is used in combination with metformin, while studies suggest an increased risk of peripheral edema if used in combination with a thiazolidinedione.[14][15][16][17]
Contraindications
Repaglinide is not contraindicated in many instances - it has been utilized in patients with chronic kidney disease to good effect. It is deemed safer in such cases than metformin and sulfonylureas.
Contraindications does include[13][6][18]:
- Hypersensitivity to any of the components of the oral preparation
- Diabetes mellitus type 1 and diabetic ketoacidosis
- Severe liver dysfunction
- Concomitant use of gemfibrozil or clopidogrel
- Concomitant use of NPH insulin
Monitoring
Periodic measurements of fasting glucose and HBA1c are recommended for determining the efficacy of treatment. Dose adjustments should be monitored by fasting glucose alone for responsivity at a minimum of 1 week following the start of treatment.[5]
Repaglinide is metabolized by the hepatic isoenzymes CYP3A4 and CYP2C8. As such, it carries a low therapeutic index as a substrate for inactivation and clearance and is susceptible to concentration changes in the presence of hepatic inducers and inhibitors.
Dose adjustment and closer monitoring may be necessary for concomitant use of the following therapeutic agents:
- Fenofibrate
- Ketoconazole
- Trimethoprim
- Cyclosporine
- Rifampin
- Estrogen-based therapies
- Simvastatin
- Nifedipine
- Clarithromycin
Besides, grapefruit juice may cause pharmacokinetic interactions.[19][20][5]
Toxicity
Severe hypoglycemia may induce seizures, coma, or other neurological impairments and requires immediate hospitalization and medical attention.
Hypoglycemia without loss of consciousness may present with drowsiness, confusion, profuse sweating, agitation, abdominal pain, and tachycardia.
Intentional overdose in large quantities may be managed with activated charcoal if caught exceptionally early. In the asymptomatic patient, a watch-and-wait approach with repeated blood glucose measurements for 24 hours may suffice. It is important to note that despite the short duration of action, overdose with repaglinide may lead to more prolonged hypoglycemia.
In unintentional excessive ingestion, prompt feeding may be sufficient to alleviate symptoms. In more severe cases, glucagon subcutaneous or intramuscular injection is recommended (1 mg for weights greater than 25 kg). Failure to respond to glucagon should be addressed with a 20% glucose intravenous infusion.[21][22]
Enhancing Healthcare Team Outcomes
Management of diabetes mellitus type 2 is an interprofessional process with the patient at the center of care.
All treatment should consider the patients' preferences, and patients should always be well informed and encouraged to make their own decisions about their care.
Patient education is key to the management of diabetes mellitus type 2, and it is the healthcare professional's responsibility to ensure all guidance is evidence-based, goal-oriented, and suitably informative.[17][5]
Evidence has suggested that educating patients on the self-management of their diabetes leads to improved clinical outcomes, as does input from specialists outside of the medical team, including but not limited to dieticians and occupational therapists. Information regarding possible drug-drug interactions, dosing alterations, and organ failure prevention is provided by specialists.[23][24]
Research suggests there may be benefits in switching to repaglinide from other antihyperglycemic agents in the elderly. Pharmacists and specialists should be trained in providing adequate education, risks versus benefits, and support clinicians (MDs) DOs, NPs, PAs) in making this transition. The interprofessional approach will yield improved patient results with targeted medication management and reduce adverse events.[25][26] [Level 5]
References
. Repaglinide. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000151]
Gomis R. Repaglinide as monotherapy in Type 2 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 1999:107 Suppl 4():S133-5 [PubMed PMID: 10522838]
Owens DR. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs. Diabetic medicine : a journal of the British Diabetic Association. 1998:15 Suppl 4():S28-36 [PubMed PMID: 9868989]
Level 3 (low-level) evidenceMollar-Puchades MA, Martin-Cortes A, Perez-Calvo A, Diaz-Garcia C. Use of repaglinide on a pregnant woman during embryogenesis. Diabetes, obesity & metabolism. 2007 Jan:9(1):146-7 [PubMed PMID: 17199735]
Level 3 (low-level) evidenceLandgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs & aging. 2000 Nov:17(5):411-25 [PubMed PMID: 11190420]
Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Current drug metabolism. 2011 Jan:12(1):57-69 [PubMed PMID: 21303332]
Level 3 (low-level) evidenceHatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical pharmacokinetics. 2002:41(7):471-83 [PubMed PMID: 12083976]
Plosker GL, Figgitt DP. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. PharmacoEconomics. 2004:22(6):389-411 [PubMed PMID: 15099124]
Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2000 Sep:24 Suppl 3():S21-31 [PubMed PMID: 11063281]
Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treatments in endocrinology. 2003:2(6):401-14 [PubMed PMID: 15981944]
Level 3 (low-level) evidenceSunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. European journal of pharmacology. 2001 Nov 9:431(1):119-25 [PubMed PMID: 11716850]
Level 3 (low-level) evidenceSeedher N, Kanojia M. Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin. Chemical biology & drug design. 2008 Oct:72(4):290-6. doi: 10.1111/j.1747-0285.2008.00704.x. Epub [PubMed PMID: 18844675]
Owens DR, McDougall A. Repaglinide: prandial glucose regulation in clinical practice. Diabetes, obesity & metabolism. 2000 Mar:2 Suppl 1():S43-8 [PubMed PMID: 11225759]
Azimova K, San Juan Z, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. The Ochsner journal. 2014 Winter:14(4):616-32 [PubMed PMID: 25598727]
Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM, Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes care. 2004 Jun:27(6):1265-70 [PubMed PMID: 15161773]
Level 1 (high-level) evidenceCho HY, Ngo L, Kim SK, Choi Y, Lee YB. Bioequivalence of a fixed-dose repaglinide/metformin combination tablet and equivalent doses of repaglinide and metformin tablets . International journal of clinical pharmacology and therapeutics. 2018 Jun:56(6):292-300. doi: 10.5414/CP203199. Epub [PubMed PMID: 29648532]
Level 1 (high-level) evidenceOmori K, Nomoto H, Nakamura A, Takase T, Cho KY, Ono K, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. Journal of diabetes investigation. 2019 Mar:10(2):367-374. doi: 10.1111/jdi.12889. Epub 2018 Sep 15 [PubMed PMID: 29963781]
Level 1 (high-level) evidenceZanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss medical weekly. 2012:142():w13629. doi: 10.4414/smw.2012.13629. Epub 2012 Sep 13 [PubMed PMID: 22987488]
Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clinical pharmacokinetics. 2007:46(2):93-108 [PubMed PMID: 17253883]
Marshall V, Wilton L, Shakir S. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. Acta diabetologica. 2006 May:43(1):6-13 [PubMed PMID: 16710643]
Level 2 (mid-level) evidenceSpiller HA. Management of antidiabetic medications in overdose. Drug safety. 1998 Nov:19(5):411-24 [PubMed PMID: 9825953]
Elling R, Spehl MS, Wohlfarth A, Auwaerter V, Hermanns-Clausen M. Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination. Clinical toxicology (Philadelphia, Pa.). 2016:54(2):158-60. doi: 10.3109/15563650.2015.1122793. Epub 2015 Dec 22 [PubMed PMID: 26692235]
Benson GA, Sidebottom A, Hayes J, Miedema MD, Boucher J, Vacquier M, Sillah A, Gamam S, VanWormer JJ. Impact of ENHANCED (diEtitiaNs Helping pAtieNts CarE for Diabetes) Telemedicine Randomized Controlled Trial on Diabetes Optimal Care Outcomes in Patients with Type 2 Diabetes. Journal of the Academy of Nutrition and Dietetics. 2019 Apr:119(4):585-598. doi: 10.1016/j.jand.2018.11.013. Epub 2019 Jan 31 [PubMed PMID: 30711463]
Level 1 (high-level) evidenceAdam L, O'Connor C, Garcia AC. Evaluating the Impact of Diabetes Self-Management Education Methods on Knowledge, Attitudes and Behaviours of Adult Patients With Type 2 Diabetes Mellitus. Canadian journal of diabetes. 2018 Oct:42(5):470-477.e2. doi: 10.1016/j.jcjd.2017.11.003. Epub 2017 Nov 23 [PubMed PMID: 29449096]
Wang CY, Yu NC, Sheu WH, Tsai ST, Tai TY. Team care of type 2 diabetes mellitus in Taiwan. Diabetes research and clinical practice. 2014 Dec:106 Suppl 2():S309-13. doi: 10.1016/S0168-8227(14)70735-1. Epub [PubMed PMID: 25550059]
Valensi P, Picard S, Pathak A. Type 2 diabetes: Why should diabetologists and cardiologists work more closely together? Diabetes & metabolism. 2019 Dec:45(6):501-504. doi: 10.1016/j.diabet.2019.07.007. Epub 2019 Aug 5 [PubMed PMID: 31394190]